News

Vertex Pharmaceuticals' (NASDAQ: VRTX) stock has climbed nearly 20% so far this year, and for good reason. The biotech company completed a regulatory submission for what may become its next

Novavax (NASDAQ: NVAX) shares soared more than 30% in one trading session this week. That's a huge gain for any stock. But it's particularly impressive for Novavax. The biotech stock has been in the

Shares of telecom giant AT&T (NYSE: T) fell 13.4% in the first half of 2023, according to data from S&P Global Market Intelligence. Over the same time span, the S&P 500 market index gained 15.9%. In

Amid last year's difficult market, you may not have put all of your investable money to work -- in which case, you might have cash sitting on the sidelines. This would be the perfect time to deploy

Fool.com contributor Parkev Tatevosian compares Deere (NYSE: DE) and AT&T (NYSE: T) to determine which is the better dividend stock for passive income investors.

*Stock prices used were the

Shares of Novavax (NASDAQ: NVAX) were up more than 24% as of 12:08 p.m. ET on Monday after the biotech company said Friday that Canada will pay $349.6 million for unused COVID-19 shots from the

Biogen (NASDAQ: BIIB) once stood out as one of the most successful biotech companies. It's portfolio of blockbuster multiple sclerosis drugs grew revenue into the billions of dollars. But as the

Some decisions are hard. Others, however, are so easy that they require much less thought.

Three Motley Fool contributors believe they've found stocks to buy that definitely fall into the latter

Pharmaceutical companies depend on the patent protection they receive for their goods, so it's never a good day when it is stripped away. That was the misfortune suffered by global pharmaceutical

Shares of transplant diagnostics company CareDx (NASDAQ: CDNA) were up more than 20% as of 12:20 p.m. ET on Friday after a decision by the Centers for Medicare & Medicaid Services (CMS) that could

Despite lingering economic issues, the broader stock market has recovered this year. But some companies are failing to keep up for a variety of reasons. Take AbbVie (NYSE: ABBV) and Amgen (NASDAQ:

Biotech giant Regeneron (NASDAQ: REGN) has been an outstanding performer over the past year. And although its stock is still up by 20% in the trailing-12-month period, the company's shares recently

AbbVie (NYSE: ABBV) is a leading pharmaceutical company that rewards its shareholders with a generous dividend policy. The company has a history of increasing its dividends for more than 50 years in

Novocure (NASDAQ: NVCR) shares dropped after publishing the results of an important clinical trial. The headlines looked positive at first glance, but the study raised concerns that lung cancer

Shares of clinical-stage biotech company Caribou Biosciences (NASDAQ: CRBU) were up more than 58% as of 11:15 a.m. ET on Thursday after Pfizer (NYSE: PFE) made a $25 million equity investment in the

If you're looking to invest in the stock market this summer, there are many great options out there to consider. Whether you're after dividends, growth, or simply long-term stability, there are

Cathie Wood's Ark Investment Management has deemed CRISPR/Cas 9 genome editing as "biotech's breakthrough of the century." Back in 2018, Ark identified this gene-editing tool as a potential $2

There are many ways to determine whether a stock is cheap, but one way of doing so is determining whether there is substantial upside potential for the company. And while the market often bids up

Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and Novavax (NASDAQ: NVAX) were all popular stocks to own when demand for COVID vaccines was strong. But these companies are all preparing for what's

Regeneron Pharmaceuticals' (NASDAQ: REGN) sales growth has been lackluster in recent periods. The company is hoping that a higher-dose version of its eye medication Eylea could be a catalyst for